Shifting Towards Empagliflozin First‐Line Therapy in Glycogen Storage Disease Type Ib: A Nationwide Real‐World Study
Journal of Inherited Metabolic Disease · 2026-05 · 49 (3)
DOI: 10.1002/jimd.70198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 03.05.2026. Verfasst von Sema Kalkan Uçar und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Ege University Faculty of Medicine, İzmir, Türkiye. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type I, Benzhydryl Compounds, Glucosides, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neutrophil dysfunction and neutropenia are burdensome findings in glycogen storage disease type Ib (GSDIb). Treatment with granulocyte‐colony stimulating factor (G‐CSF) often corrects neutropenia but fails to improve clinical symptoms like inflammatory bowel disease (IBD). Recently, empagliflozin (EMPA) was shown to correct the neutrophil dysfunction and its clinical consequences. It is increasingly used as first‐line monotherapy, but long‐term, real‐world data are lacking. This nation‐wide retrospective study investigated 42 GSD1b patients (36 children) treated with EMPA as first‐line monotherapy and compared them with those receiving combination therapy with G‐CSF and treatment‐naïve patients (I:EMPA first‐line monotherapy [ n = 9]; II:G‐CSF monotherapy [ n = 7]; III:EMPA plus G‐CSF [ n = 16]; and IV: neither EMPA nor GCSF [ n = 10]). Pediatric (P) patients were evaluated separately. In pediatric patients receiving EMPA as first‐line monotherapy (P‐I) and those with EMPA plus G‐CSF (P‐III), the frequency of infections, hospital admissions, and IBD was significantly lower than in patients receiving GCSF‐monotherapy (P‐II) or no treatment (P‐IV). Additionally, significantly improved weight gain was observed in P‐I. While clinical improvement related to correction of neutrophil dysfunction was seen with EMPA first‐line monotherapy (P‐I), significant improvement in absolute neutrophil count (ANC) and hemoglobin levels was only seen in P‐III with additional G‐CSF treatment. In three cases, EMPA was safely paused and subsequently resumed, for example, during pregnancy or liver transplantation. First‐line EMPA monotherapy effectively corrects clinical symptoms of neutrophil dysfunction in GSD Ib patients, even in the absence of a statistically significant increase in ANC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Ege University Faculty of Medicine, İzmir, Türkiye.
- Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Cukurova University Faculty of Medicine, Adana, Türkiye.
- Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, İstanbul University Faculty of Medicine, İstanbul, Türkiye.
- Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.
- Division of Pediatric Metabolism and Nutrition, Department of Pediatrics, Marmara University Faculty of Medicine, İstanbul, Türkiye.
- Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Faculty of Medicine, Harran University, Şanlıurfa, Türkiye.
ORCID-Profile: Sema Kalkan Uçar, Ayşe Çiğdem Aktuğlu Zeybek, Pelin Teke Kısa, Ayça Burcu Kahraman, Merve Yoldaş Çelik, Meryem Karaca, Tanyel Zübarioğlu, Havva Yazıcı, Fatma Derya Bulut, Fehime Erdem Karapınar, Ezgi Burgaç, Ertuğrul Kıykım, Alperen Elek, Deniz Yılmaz Karapınar
Zitieren
APA
Uçar, S. K., Mungan, N. Ö., Gökçay, G. F., Zeybek, A. Ç. A., Kılavuz, S., Güneş, S., Kardaş, F., Kısa, P. T., Çıkı, K., Yavaş, A. K., Kahraman, A. B., Çelik, M. Y., Canda, E., Kor, D., Karaca, M., Zübarioğlu, T., Genç, E., Yazıcı, H., Bulut, F. D., …, & Karapınar, D. Y. (2026). Shifting Towards Empagliflozin First‐Line Therapy in Glycogen Storage Disease Type Ib: A Nationwide Real‐World Study. Journal of Inherited Metabolic Disease, 49(3). https://doi.org/10.1002/jimd.70198
Vancouver
Uçar SK, Mungan NÖ, Gökçay GF, Zeybek AÇA, Kılavuz S, Güneş S, et al. Shifting Towards Empagliflozin First‐Line Therapy in Glycogen Storage Disease Type Ib: A Nationwide Real‐World Study. Journal of Inherited Metabolic Disease. 2026;49(3). doi:10.1002/jimd.70198
BibTeX
@article{Uar2026,
author = {Uçar, Sema Kalkan and Mungan, Neslihan Önenli and Gökçay, Gülden Fatma and Zeybek, Ayşe Çiğdem Aktuğlu and Kılavuz, Sebile and Güneş, Seda and Kardaş, Fatih and Kısa, Pelin Teke and Çıkı, Kısmet and Yavaş, Aynur Küçükçongar and Kahraman, Ayça Burcu and Çelik, Merve Yoldaş and Canda, Ebru and Kor, Deniz and Karaca, Meryem and Zübarioğlu, Tanyel and Genç, Emine and Yazıcı, Havva and Bulut, Fatma Derya and Kılıç, Şebnem and Aghakıshılı, Hanım and Karapınar, Fehime Erdem and Burgaç, Ezgi and Kıykım, Ertuğrul and Elek, Alperen and Kardaş, Nihal and Ünal, Ekrem and Karapınar, Tuba Hilkay and Albayrak, Meryem and Albayrak, Canan and Ünüvar, Ayşegül and Wortmann, Saskia B and Karapınar, Deniz Yılmaz},
title = {Shifting Towards Empagliflozin First‐Line Therapy in Glycogen Storage Disease Type Ib: A Nationwide Real‐World Study},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
volume = {49},
number = {3},
doi = {10.1002/jimd.70198}
}
EUVIMED